Browse Category by Medical Review
Medical Review

Mikhail Blagosklonny Is Enhancing Scientific Research Through Oncotarget

Mikhail Blagosklonny is a cancer and aging scientist. He is also a professor of oncology at Roswell Park Cancer Institute. Mikhail has been a committed editor-in-chief for Oncotarget, a weekly peer-reviewed journal. Over the years, the periodical has been publishing papers on oncology and other related fields. Through Mikhail’s visionary leadership, Oncotarget has published many journals from different authors. The journal has been of great importance to experts and the public as it has broadened their understanding of oncology.

Mikhail’s mission is to eliminate boundaries between different fields of biomedical science through publishing research papers on broad topics. These subjects include aging, pathology, immunology and microbiology, chromosome, autophagy and cell death. Through Oncotarget, Mikhail and other scientists strive to ensure that people are disease-free. To this end, they encourage the application of clinical science to treat different diseases. The journal has continued to stamp its authority in the field of oncology considering that it is peer reviewed.

Mikhail Blagosklonny pursued his education at First Pavlov State Medical University in St. Petersburg. He graduated with an MD in Internal Medicine. Later, he returned to the esteemed institution to complete his PhD in Experimental Medicine and Cardiology. In 2002, Mikhail joined New York Medical College as an associate professor. In 2009, he agreed to work for Ordway Research Institute as a senior scientist. Dr. Mikhail’s research has focused on oncogens and tumor suppressors, mitosis, apoptosis, signal transduction, cell cycle, and anticancer therapeutics. He is credited for coming up with the hyper function theory of aging and anti-cancer therapies known as chemotherapeutic engineering and cell cyclotherapy. The scientist formulated a hypothesis to study the possible role of TOR signaling in cancer and aging. Mikhail is a strong advocate for rapamycin, a cancer drug that prolongs the life of a cancer patient.

Learn more: http://www.nature.com/cdd/about/biographies.html

Blagosklonny is the editor-in-chief of Aging and Cell Cycle. He serves as an associate editor for the American Journal of Pathology, PLOS ONE, and Internal Journal of Cancer. Mikhail, who co-founded Oncoscience, is also affiliated with Cell Death and Differentiation, Autophagy and Cancer Biology & Therapy. He is the author of over 300 publications, including research articles, reviews and book chapters. Mikhail’s contribution in the field of oncology and cancer research has made him one of the most sought after oncology researchers in the world. Visit ResearchGate.Net to know more about Mikhail’s latest work.

Medical Review

The Six Years of Oncotarget

Oncotarget is an open access medical journal in the English Language. It is a multidisciplinary peer-reviewed journal and weekly published by Impact Journals. The magazine was launched in 2010. Andrei V. Gudkov and Mikhail Blagosklonny are the editors-in-chief of Oncotarget. Bibliographic databases like Scopus, Index Medicus, Science Citation Index Expanded, MEDLINE, BIOSIS Previews, and PubMed have indexed and abstracted Oncotarget. Despite having a great repute, it has been criticized for its reviewing process on scimagojr.com. Among all journals in Oncology, Oncotarget ranks No.01. It has an impact factor of 5.415 according to the Journal Citation Reports.

The mission of Oncology is to make science research widely and rapidly available, and have no borders between specialties. The primary focus of Oncotarget is to publish research papers in cancer. However, the journal also needs to publish papers in other fields due to complex nature of tumor development, and its connection with other things. Therefore, it is contributing to the scientific progress under the leadership of well-known scientists. Due to its success, Oncotarget decided to launch more sections. The current sections of the journal are Pharmacology, Cardiology, Aging, Metabolism, Microbiology, Cell & Mol Biology, Neuroscience, and Endocrinology.

The journal follows COPE Code of Conduct for Journal Editors and Publishers. Editors, reviewers, and authors follow ICJME’s Recommendations for ethical behavior guidelines on endnote.com. Brief guidelines for editors, authors, and reviewers are also available on the journal’s website. It is highly recommended that authors read the publishing policies before they submit an article.

People can access the archives of Oncotarget on its website. All volumes of the journal from 2010 to 2016 are uploaded there. Anyone can download and print articles for his research work. To speed up the search, Oncotarget has provided a special search feature on its website. All one has to do is to write some details like the category, author’s name, title, date, discipline, and keyword(s). Within a few seconds, that article will be on the screen. The editors of Oncotarget are aware of the importance of social media. Therefore, the journal has accounts on popular social media websites like Facebook, Twitter, YouTube, Google+, and LinkedIn.

Oncotarget has the honor of publishing two highly important research studies. On January 2013, the journal published a study titled MET amplification as a potential therapeutic target in gastric cancer. On November 2016, Oncotarget published a study which showed that E-cigarettes damaged gum tissues. Professor Irfan Rahman of UR School of Medicine and Dentistry led the study. Reference: https://www.researchgate.net/journal/1949-2553_Oncotarget